ArticleCancer medicine2025
Navigating the Prognostic Complexity of IgH Cytogenetic Abnormalities in Multiple Myeloma Among Diverse IgH Cytogenetic Abnormalities-Involved High-Risk Stratifications.
Article in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectiveTo evaluate the clinical and prognostic significance of immunoglobulin heavy chain (IgH) cytogenetic abnormalities in patients with newly diagnosed multiple myeloma (NDMM) and explore their association with other high-risk cytogenetic features. PATIENTS AND
methodsWe retrospectively analyzed 503 NDMM patients treated between February 1, 2016, and February 29, 2024. Cytogenetic abnormalities were identified by fluorescence in situ hybridization.
resultsThe study uncovered a significant correlation between IgH cytogenetic abnormality and an increased prevalence of anemia (p < 0.001), thrombocytopenia (p = 0.005), and the presence of high-risk cytogenetic aberrations, including +1q21 (p < 0.001) and P53 deletion (p = 0.001). Patients afflicted with IgH cytogenetic abnormality were found to have more advanced stages of the disease, as indicated by higher Disease Stage (p < 0.001), International Staging System (p = 0.018), Revised International Staging System (RISS) (p < 0.001), and Second Revision of the International Staging System (p < 0.001). This cytogenetic abnormality was also linked to a markedly diminished progression-free survival (PFS) across RISS I-II, yet autologous stem cell transplantation (ASCT) offered significant improvement for PFS (p < 0.05). Notably, the specific t(14;16) and t(14; undefined) were significantly associated with shorter PFS (p < 0.001) and shorter overall survival (OS) (p < 0.05). Additionally, the confluence of IgH cytogenetic abnormality with other cytogenetic abnormalities, particularly +1q21, P53 deletion, RB/D13S319 deletion, and elevated LDH level, was found to exacerbate the disease outcome.
conclusionIgH cytogenetic abnormalities indicate aggressive disease and poorer survival in NDMM, especially when accompanied by other high-risk markers. ASCT may mitigate these adverse outcomes, supporting its role in individualized treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.